Translations:SGLT2 inhibitor/23/ja: Difference between revisions

From Azupedia
Jump to navigation Jump to search
VisualWikitext
Created page with "{| class="wikitable" |+ 表2: 様々なSGLT-2阻害剤の薬物動態パラメータ |- ! 薬物名 !! 生物学的利用能 !! タンパク質結合 !! 最大（時間） !! t1/2 (hours) !! Cmax !! SGLT1に対するSGLT2選択性 |- | Canagliflozin/ja || 65% (300 mg dose) || 99% || 1–2 || 10.6 (100 mg dose); 13.1 (300 mg dose) || 1096 ng/mL (100 mg dose); 3480 ng/mL (300 mg dose) || 250 fold |- | Dapagliflozin/ja || 78% || 91..."
 
No edit summary
 
Line 2: Line 2:
|+ 表2: 様々なSGLT-2阻害剤の薬物動態パラメータ
|+ 表2: 様々なSGLT-2阻害剤の薬物動態パラメータ
|-
|-
! 薬物名 !! 生物学的利用能 !! タンパク質結合 !! 最大（時間） !! t1/2 (hours) !! Cmax !! SGLT1に対するSGLT2選択性
! 薬物名 !! 生物学的利用能 !! タンパク質結合 !! tmax（時間） !! t1/2 (hours) !! Cmax !! SGLT1に対するSGLT2選択性
|-
|-
| [[Canagliflozin/ja]] || 65% (300 mg dose) || 99% || 1–2 || 10.6 (100 mg dose); 13.1 (300 mg dose) || 1096 ng/mL (100 mg dose); 3480 ng/mL (300 mg dose) || 250 fold
| [[Canagliflozin/ja]] || 65% (300 mg dose) || 99% || 1–2 || 10.6 (100 mg dose); 13.1 (300 mg dose) || 1096 ng/mL (100 mg dose); 3480 ng/mL (300 mg dose) || 250 fold

Latest revision as of 21:14, 12 February 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (SGLT2 inhibitor)
{| class="wikitable"
|+ TABLE 2: PHARMACOKINETIC PARAMETERS OF VARIOUS SGLT-2 INHIBITORS
|-
! Name of drug !! Bioavailability !! Protein binding !! tmax (hours) !! t1/2 (hours) !! Cmax !! SGLT2 selectivity over SGLT1
|-
| [[Canagliflozin]] || 65% (300 mg dose) || 99% || 1–2 || 10.6 (100 mg dose); 13.1 (300 mg dose) || 1096 ng/mL (100 mg dose); 3480 ng/mL (300 mg dose) || 250 fold
|-
| [[Dapagliflozin]] || 78% || 91% || 1–1.5 || 12.9 || 79.6 ng/mL (5 mg dose); 165.0 ng/mL (10 mg dose) || 1200 fold
|-
| [[Empagliflozin]] || 90–97% (mice); 89% (dogs); 31% (rats) || 86.20% || 1.5 || 13.2 (10 mg dose); 13.3h (25 mg dose) || 259nmol/L (10 mg dose); 687nmol/L (25 mg dose) || 2500 fold
|-
| [[Ertugliflozin]] || 70-90% || 95% || 0.5-1.5 || 11-17 ||268 ng/mL (15 mg dose) || 2000 fold
|-
| [[Ipragliflozin]] (50 mg) || 90% || 96.30% || 1 || 15–16 (50 mg dose) || 975 ng/mL || 360 fold
|-
| [[Luseogliflozin]] || 35.3% (male rats); 58.2% (female rats); 92.7% (male dogs) || 96.0–96.3% || 0.625±0.354 || 9.24±0.928 || 119±27.0 ng/mL || 1650 fold
|-
表2: 様々なSGLT-2阻害剤の薬物動態パラメータ
薬物名 生物学的利用能 タンパク質結合 tmax（時間） t1/2 (hours) Cmax SGLT1に対するSGLT2選択性
Canagliflozin/ja 65% (300 mg dose) 99% 1–2 10.6 (100 mg dose); 13.1 (300 mg dose) 1096 ng/mL (100 mg dose); 3480 ng/mL (300 mg dose) 250 fold
Dapagliflozin/ja 78% 91% 1–1.5 12.9 79.6 ng/mL (5 mg dose); 165.0 ng/mL (10 mg dose) 1200 fold
Empagliflozin/ja 90–97% (mice); 89% (dogs); 31% (rats) 86.20% 1.5 13.2 (10 mg dose); 13.3h (25 mg dose) 259nmol/L (10 mg dose); 687nmol/L (25 mg dose) 2500 fold
Ertugliflozin/ja 70-90% 95% 0.5-1.5 11-17 268 ng/mL (15 mg dose) 2000 fold
イプラグリフロジン (50 mg) 90% 96.30% 1 15–16 (50 mg dose) 975 ng/mL 360 fold
Luseogliflozin/ja 35.3% (male rats); 58.2% (female rats); 92.7% (male dogs) 96.0–96.3% 0.625±0.354 9.24±0.928 119±27.0 ng/mL 1650 fold
Retrieved from "https://wiki.tiffa.net/w/index.php?title=Translations:SGLT2_inhibitor/23/ja&oldid=114116"